CN113413402B - Application of Plum Blossom Extract in the Preparation of Medicines for Helicobacter pylori Infection - Google Patents

Application of Plum Blossom Extract in the Preparation of Medicines for Helicobacter pylori Infection Download PDF

Info

Publication number
CN113413402B
CN113413402B CN202110880525.9A CN202110880525A CN113413402B CN 113413402 B CN113413402 B CN 113413402B CN 202110880525 A CN202110880525 A CN 202110880525A CN 113413402 B CN113413402 B CN 113413402B
Authority
CN
China
Prior art keywords
extract
prunus
plum blossom
treatment
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110880525.9A
Other languages
Chinese (zh)
Other versions
CN113413402A (en
Inventor
王睿君
白爽
王儒帅
潘元明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiliated Hospital Of Inner Mongolia Medical University Cardiovascular Research Institute Of Inner Mongolia Autonomous Region
Original Assignee
Affiliated Hospital Of Inner Mongolia Medical University Cardiovascular Research Institute Of Inner Mongolia Autonomous Region
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiliated Hospital Of Inner Mongolia Medical University Cardiovascular Research Institute Of Inner Mongolia Autonomous Region filed Critical Affiliated Hospital Of Inner Mongolia Medical University Cardiovascular Research Institute Of Inner Mongolia Autonomous Region
Priority to CN202110880525.9A priority Critical patent/CN113413402B/en
Publication of CN113413402A publication Critical patent/CN113413402A/en
Application granted granted Critical
Publication of CN113413402B publication Critical patent/CN113413402B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明公开了梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用,属于药物技术领域,本发明首次确定了梅花草提取物在体外可以抑制Hp的毒力与定植能力,并通过动物实验验证得到梅花草提取物可有效抑制Hp的感染与炎症状态,其单独用药的效果优于或等同于三联或四联的治疗效果,将其与三联或四联联用可协同提高对Hp感染后的根除效果和胃黏膜保护效果;采用梅花草提取物对Hp感染疾病进行治疗,成本低,疗程短,治疗方便;本发明对Hp感染疾病的治疗提供了新思路,对Hp的临床治疗推广具有重大意义。

Figure 202110880525

The invention discloses the application of Plum Blossom extract in preparing medicines for treating Helicobacter pylori infection, belonging to the technical field of medicine. The invention determines for the first time that Plum Blossom extract can inhibit the virulence and colonization ability of H. Experiments have verified that the extract of Prunus chinensis can effectively inhibit the infection and inflammatory state of H. pylori. The effect of its single medication is better than or equal to the therapeutic effect of triple or quadruple combination. It can be used in combination with triple or quadruple combination to synergistically improve the treatment of H. pylori infection. After the eradication effect and gastric mucosa protection effect; the use of Prunus chinensis extract for the treatment of H. pylori infection has low cost, short course of treatment and convenient treatment; the present invention provides a new idea for the treatment of H. pylori infection, and is popularized for the clinical treatment of H. pylori has great significance.

Figure 202110880525

Description

梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用Application of Meihuacao Extract in the Preparation of Drugs for Treating Helicobacter Pylori Infection Diseases

技术领域technical field

本发明属于医药技术领域,具体涉及梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用。The invention belongs to the technical field of medicines, and in particular relates to the application of an extract of Prunus chinensis in the preparation of medicines for treating Helicobacter pylori infection diseases.

背景技术Background technique

梅花草(Parnassis palustris L.)为虎耳草科梅花草属植物突隔梅花草的全草或根,又称白侧草、马蹄草等,是蒙古族历代和民间常用的特色蒙药,蒙古名为那木戛纳、乌力地格和那木日因查干-其其格等。在现代蒙医临床应用是用于治疗肿瘤及其相关疾病的常用蒙药材之一。梅花草气味甘、苦,无明显毒性,具有清热解毒、破痞、消肿排脓和抑希日等功效,临床主要用于治疗腑器热性希日病和热性痞症,即治疗肝、胆肿瘤及部分肠道肿瘤(如结肠肿瘤)等,也可以治疗黄疸型肝炎、咽喉炎、腮腺炎、脉管炎和肺结核等。Prunus palustris (Parnassis palustris L.) is the whole herb or root of the saxifrage plant Prunus genus, also known as white side grass, horseshoe grass, etc. For Namu Cannes, Uldige and Namu Riyinchagan-Qiqige and so on. It is one of the commonly used Mongolian medicinal materials for the treatment of tumors and related diseases in the clinical application of modern Mongolian medicine. Plum blossom grass smells sweet and bitter, without obvious toxicity, and has the functions of clearing away heat and detoxifying, dispelling swelling, reducing swelling and discharging pus, and suppressing sunburn. , gallbladder tumors and some intestinal tumors (such as colon tumors), etc., can also treat jaundice hepatitis, pharyngitis, mumps, vasculitis and tuberculosis.

幽门螺杆菌(Helicobacter pylori,Hp)是一种广泛定植于人胃中的微需氧革兰氏阴性杆菌。世界上有50%以上的人被其感染,研究证实幽门螺杆菌感染与慢性胃炎、胃溃疡、十二指肠溃疡和胃癌的高发率密切相关。目前临床上治疗幽门螺杆菌主要方法有三联或四联疗法,即2种或3种抗生素结合1种质子泵抑制剂或铋剂。因胃环境的特殊性及胃的排空导致幽门螺杆菌治疗用药量大、疗程长、成本高、副作用大,致使病人依从性差,部分病人未达到完整的疗程就停止服药,另外,幽门螺杆菌对使用的抗生素易产生耐药性,甚至出现了对6种抗生素的耐药菌株,幽门螺杆菌还容易重新感染。因此,根治幽门螺杆菌感染已成为医学难题。中药复方制剂治疗幽门螺杆菌虽然具有很好的疗效,但其成分不清、疗程长、服用不便且成本较西药更高。Helicobacter pylori (Hp) is a microaerophilic Gram-negative bacillus widely colonized in the human stomach. More than 50% of people in the world are infected by it. Studies have confirmed that Helicobacter pylori infection is closely related to the high incidence of chronic gastritis, gastric ulcer, duodenal ulcer and gastric cancer. At present, the main methods for the clinical treatment of Helicobacter pylori include triple or quadruple therapy, that is, 2 or 3 antibiotics combined with 1 proton pump inhibitor or bismuth. Due to the particularity of the gastric environment and the emptying of the stomach, the treatment of Helicobacter pylori requires a large amount of medication, a long course of treatment, high costs, and large side effects, resulting in poor patient compliance. Some patients stop taking medicine before reaching the complete course of treatment. In addition, Helicobacter pylori It is easy to produce drug resistance to the antibiotics used, and even drug-resistant strains to 6 kinds of antibiotics have appeared, and Helicobacter pylori is also easy to re-infect. Therefore, eradicating Helicobacter pylori infection has become a medical problem. Although traditional Chinese medicine compound preparations have good curative effects in treating Helicobacter pylori, their ingredients are unclear, the course of treatment is long, it is inconvenient to take, and the cost is higher than that of western medicines.

目前尚未发现以梅花草提取物来制备治疗幽门螺杆菌感染的疾病的药物的相关报道。At present, there is no relevant report on the preparation of medicines for treating diseases infected by Helicobacter pylori with the extract of Prunus chinensis.

发明内容Contents of the invention

为解决现有技术中的上述问题,本发明提供了梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用。In order to solve the above-mentioned problems in the prior art, the present invention provides the application of the extract of Prunus chinensis in the preparation of medicines for treating Helicobacter pylori infection.

为实现上述目的,本发明提供了如下技术方案:To achieve the above object, the present invention provides the following technical solutions:

本发明提供了梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用。The invention provides the application of the extract of Prunus chinensis in the preparation of medicine for treating Helicobacter pylori infection.

进一步地,所述幽门螺杆菌感染疾病为胃炎、胃溃疡、十二指肠溃疡或胃癌。Further, the Helicobacter pylori infection disease is gastritis, gastric ulcer, duodenal ulcer or gastric cancer.

进一步地,所述梅花草提取物的制备方法,包括以下步骤:Further, the preparation method of the quince extract comprises the following steps:

梅花草有机相提取物的制备:采用乙醇对取梅花草进行加热回流提取,得到提取液,之后除去提取液中的乙醇,干燥后得到梅花草有机相提取物;Preparation of the organic phase extract of Prunus chinensis: heating and reflux extracting the Prunus chinensis with ethanol to obtain an extract, then removing the ethanol in the extract, and drying to obtain the organic phase extract of Prunus chinense;

梅花草水相提取物的制备:采用水对梅花草进行加热浸提,过滤得浸提液,之后浓缩,对得到的浓缩液干燥,得到梅花草水相提取物;Preparation of the water-phase extract of Prunus chinensis: heating and leaching Prunus chinensis with water, filtering to obtain the extract, concentrating, drying the obtained concentrated solution, and obtaining the water-phase extract of Prunus chinense;

将所述梅花草有机相提取物及所述梅花草水相提取物等质量混合后得到所述梅花草提取物。The Herba Prunus organic phase extract and the Herba Prunus aqueous phase extract are mixed in equal mass to obtain the Herba Prunus officinalis extract.

进一步地,梅花草有机相提取物的制备过程中,所述乙醇为95vol.%的乙醇,所述加热回流提取时,梅花草与乙醇的料液比为1g∶(1~5mL),加热温度为90-95℃,每次提取4h,共提取3次,合并3次所得的提取液,所述干燥为喷雾干燥。Further, in the preparation process of the organic phase extract of Prunus chinensis, the ethanol is 95vol.% ethanol, and during the heating and reflux extraction, the solid-liquid ratio of Plum blossom and ethanol is 1g: (1-5mL), and the heating temperature The temperature is 90-95°C, each extraction is 4h, a total of 3 extractions are made, and the extracts obtained from the 3 extractions are combined, and the drying is spray drying.

进一步地,所述喷雾干燥在喷雾干燥塔中进行,喷雾干燥塔进风温度为120℃~150℃,出风温度为90℃~95℃,雾化频率为220~300Hz,加料频率为4~6.5Hz,引风频率为20~50Hz。Further, the spray drying is carried out in a spray drying tower, the air inlet temperature of the spray drying tower is 120°C-150°C, the air outlet temperature is 90°C-95°C, the atomization frequency is 220-300Hz, and the feeding frequency is 4-300Hz. 6.5Hz, the induced wind frequency is 20~50Hz.

对梅花草乙醇提取物进行喷雾干燥能较好保留梅花草固有的芳香物质和热敏性活性成分。Spray-drying the ethanol extract of Meihuacao can better retain the inherent aromatic substances and heat-sensitive active ingredients of Meihuacao.

进一步地,梅花草水相提取物的制备过程中,采用水对梅花草进行加热浸提时,梅花草与水的料液比为1g∶(5~10mL),加热温度为90-95℃,浸提时间为1-2h,所述浓缩具体为在50-60℃下减压浓缩,所述干燥温度为65-75℃,优选采用蒸馏水对梅花草进行加热浸提。Further, in the preparation process of the aqueous phase extract of Prunus chinensis, when water is used to heat and extract Plum blossoms, the ratio of solid to water is 1g: (5-10mL), and the heating temperature is 90-95°C. The leaching time is 1-2h, the concentration is specifically concentrated under reduced pressure at 50-60°C, the drying temperature is 65-75°C, and distilled water is preferably used to heat and extract Prunus chinensis.

进一步地,所述梅花草提取物作为有效活性成分加入药学上可接受的辅料制成片剂、胶囊剂、颗粒剂、口服液、悬浮剂或注射液,各种剂型中梅花草提取物的质量占药物总质量的30-60%。Further, the Prunus quince extract is added as an effective active ingredient to pharmaceutically acceptable excipients to make tablets, capsules, granules, oral liquids, suspensions or injections, and the quality of the Prunus quince extract in various dosage forms It accounts for 30-60% of the total mass of the drug.

与现有技术相比,本发明具有以下有益效果:Compared with the prior art, the present invention has the following beneficial effects:

本发明首次确定了梅花草提取物在体外可抑制Hp的毒力与定植能力,并通过动物实验验证得到梅花草可以有效抑制Hp对小鼠胃黏膜的感染与炎症加剧,其单独用药的效果优于或等效于三联、四联的治疗效果,将其与三联或四联联用可协同提高对Hp感染后的治疗效果;The present invention confirms for the first time that the extract of Prunus chinensis can inhibit the virulence and colonization ability of H. It is equal to or equivalent to the therapeutic effect of the triple combination and the quadruple combination, and its combined use with the triple combination or the quadruple combination can synergistically improve the therapeutic effect on Hp infection;

采用梅花草提取物对Hp感染疾病进行治疗,成本低,疗程短,治疗方便;Use the extract of Plum Blossom Grass to treat Hp infection, which has low cost, short course of treatment and convenient treatment;

本发明对Hp感染疾病的治疗提供了新思路,对Hp的临床治疗具有重大意义。The invention provides a new idea for the treatment of Hp infection diseases, and has great significance for the clinical treatment of Hp.

附图说明Description of drawings

为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the accompanying drawings required in the embodiments. Obviously, the accompanying drawings in the following description are only some of the present invention. Embodiments, for those of ordinary skill in the art, other drawings can also be obtained based on these drawings without any creative effort.

图1为Hp组及梅花草处理组Hp相关毒力与定植基因(Cag A、Vac A、Bab A)的相对表达量统计图;Fig. 1 is the statistical graph of the relative expression of Hp-related virulence and colonization genes (Cag A, Vac A, Bab A) in the Hp group and the Prunella treatment group;

图2(a)及图2(b)分别为Hp感染组及梅花草处理感染Hp组的小鼠胃黏膜的大体外观形态图;Figure 2(a) and Figure 2(b) are the general appearance and morphology of the gastric mucosa of mice in the Hp infection group and the Prunus pylori treatment group infected with Hp, respectively;

图3为各组小鼠的胃黏膜HE染色图;Figure 3 is the HE staining diagram of the gastric mucosa of mice in each group;

图4为各组小鼠的胃黏膜线粒体结构的透射电镜图;Fig. 4 is the transmission electron micrograph of the mitochondrial structure of the gastric mucosa of each group of mice;

图5为各组小鼠的胃黏膜微绒毛的透射电镜图。Fig. 5 is a transmission electron microscope image of gastric mucosal microvilli of mice in each group.

具体实施方式Detailed ways

现详细说明本发明的多种示例性实施方式,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。Various exemplary embodiments of the present invention will now be described in detail. The detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features and embodiments of the present invention. It should be understood that the terminology described in the present invention is only used to describe specific embodiments, and is not used to limit the present invention.

另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。In addition, regarding the numerical ranges in the present invention, it should be understood that each intermediate value between the upper limit and the lower limit of the range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated value or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded from the range.

除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only the preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and/or materials in connection with which the documents are described. In case of conflict with any incorporated document, the contents of this specification control.

在不背离本发明的范围或精神的情况下,可对本发明说明书的具体实施方式做多种改进和变化,这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见的。本发明说明书和实施例仅是示例性的。It will be apparent to those skilled in the art that various modifications and changes can be made in the specific embodiments of the present invention described herein without departing from the scope or spirit of the present invention. Other embodiments will be apparent to the skilled person from the description of the present invention. The description and examples of the invention are illustrative only.

关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等,均为开放性的用语,即意指包含但不限于。As used herein, "comprising", "comprising", "having", "comprising" and so on are all open terms, meaning including but not limited to.

以下实施例所采用的梅花草采自内蒙古自治区赤峰市赛汗乌拉国家自然保护区,采集后将整株药品置于室内自然阴干,药材经内蒙古医科大学生药学教研室渠弼教授和蒙药学院伊丽娜教授共同鉴定为梅花草(ParnassiapalustrisLinn)。The plum blossoms used in the following examples were collected from the Saihan Ula National Nature Reserve in Chifeng City, Inner Mongolia Autonomous Region. After collection, the whole plant was placed indoors to dry naturally in the shade. The professor jointly identified it as Plum Grass (ParnassiapalustrisLinn).

本发明采用的幽门螺杆菌标准菌株SS1,由北京大学第一医院消化内科实验室保存并惠赠;所采用的雄性昆明鼠(KM鼠)为6周龄,体重在36-41g之间,购于北京维通利华实验动物技术有限公司,其实验动物生产许可证:北京百善SCXK(京)2016-0006;实验动物使用许可证:北京SYXK(京)2017-0033;所采用的三联药物:雷贝拉唑钠肠溶片:卫材药业(规格10mg*7);克拉霉素片:上海雅培(规格250mg*8);阿莫西林胶囊:珠海联邦(规格500mg*48/24),所采用的四联药物在上述三联药物的基础上,外加胶体果胶铋胶囊:山西安特(规格100mg*48);The Helicobacter pylori standard strain SS1 that the present invention adopts is preserved and donated by the Gastroenterology Laboratory of Peking University First Hospital; the male Kunming rat (KM rat) adopted is 6 weeks old, and the body weight is between 36-41g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., its experimental animal production license: Beijing Baishan SCXK (Beijing) 2016-0006; experimental animal use license: Beijing SYXK (Beijing) 2017-0033; the triple drug used: Rabeprazole Sodium Enteric-coated Tablets: Eisai Pharmaceuticals (Specification 10mg*7); Clarithromycin Tablets: Shanghai Abbott (Specification 250mg*8); Amoxicillin Capsules: Zhuhai Federation (Specification 500mg*48/24), The quadruple drugs used are based on the above triple drugs, plus colloidal pectin bismuth capsules: Shanxi Ante (specification 100mg*48);

以下不再重复描述。The description will not be repeated below.

实施例1Example 1

梅花草提取物的制备,包括以下步骤:The preparation of Prunus japonica extract comprises the following steps:

(1)梅花草的有机相提取:取干燥的梅花草全草共0.40kg,使用400ml的95vol.%乙醇加热至90℃回流提取3次,每次4小时,合并3次提取得到的提取液,挥发乙醇后,得到梅花草乙醇提取物;将上述提取物在喷雾干燥塔中进行干燥得到梅花草有机相提取物,所述喷雾干燥塔进风温度为120℃,出风温度为90℃,雾化频率为220Hz,加料频率为4Hz,引风频率为20Hz,能较好保留梅花草固有的芳香物质和热敏性活性成分。(1) Extraction of the organic phase of Prunus chinensis: take 0.40 kg of the whole dried Plum Blossom grass, use 400 ml of 95vol.% ethanol to heat to 90°C for reflux extraction 3 times, each time for 4 hours, and combine the extracts obtained by 3 extractions , after volatilizing the ethanol, the ethanol extract of Prunus chinensis is obtained; the above-mentioned extract is dried in a spray drying tower to obtain the organic phase extract of Prunus chinensis, the air inlet temperature of the spray drying tower is 120°C, and the outlet air temperature is 90°C, The atomization frequency is 220Hz, the feeding frequency is 4Hz, and the air induction frequency is 20Hz, which can better retain the inherent aromatic substances and heat-sensitive active ingredients of Meihua grass.

(2)梅花草水相提取:称取25克干燥梅花草,打粉机粉碎后,注入200ml的去离子水在90℃水浴中浸提1小时后过滤,过滤后在60℃减压浓缩得浓缩液,用0.22um的滤器对所得水相提取物进行除菌,将过滤后的浓缩液在75℃烘箱中烘干得到梅花草水相提取物,备用;(2) Aqueous phase extraction of plum blossom grass: Weigh 25 grams of dried plum blossom grass, pulverize it with a powder machine, inject 200ml of deionized water, extract it in a water bath at 90°C for 1 hour, filter it, and concentrate it under reduced pressure at 60°C after filtration. liquid, use a 0.22um filter to sterilize the obtained aqueous phase extract, dry the filtered concentrated solution in an oven at 75°C to obtain the aqueous phase extract of Prunus chinensis, and set aside;

(3)将步骤(1)所得的梅花草有机相提取物与步骤(2)所得的梅花草水相提取物等质量混合,即得所述梅花草提取物。(3) Mixing the organic phase extract of Herba Prunus obtained in step (1) with the aqueous phase extract of Herba Prunus obtained in step (2) to obtain the Herba Prunus extract.

实施例2Example 2

梅花草提取物的制备:Preparation of Prunus officinalis extract:

(1)梅花草的有机相提取:取干燥的梅花草全草共0.40kg,使用2000ml的95vol.%乙醇加热至95℃回流提取3次,每次4小时,合并3次提取得到的提取液,挥发乙醇后,得到梅花草乙醇提取物;将上述提取物在喷雾干燥塔中进行干燥得到梅花草有机相提取物,所述喷雾干燥塔进风温度为150℃,出风温度为95℃,雾化频率为300Hz,加料频率为5Hz,引风频率为30Hz,能较好保留梅花草固有的芳香物质和热敏性活性成分。(1) Extraction of the organic phase of Prunus chinensis: take 0.40 kg of the whole dried Plum chinensis, use 2000 ml of 95vol.% ethanol to heat to 95°C for reflux extraction 3 times, each time for 4 hours, and combine the extracts obtained by 3 extractions , after volatilizing ethanol, the ethanol extract of Prunus chinensis is obtained; the above-mentioned extract is dried in a spray drying tower to obtain the organic phase extract of Prunus chinensis, the air inlet temperature of the spray drying tower is 150°C, and the outlet air temperature is 95°C, The atomization frequency is 300 Hz, the feeding frequency is 5 Hz, and the air induction frequency is 30 Hz, which can better retain the inherent aromatic substances and heat-sensitive active ingredients of Meihua grass.

(2)梅花草水相提取:称取25克干燥梅花草,打粉机粉碎后,注入125ml的去离子水在95℃水浴中浸提1小时后过滤,过滤后在50℃减压浓缩得浓缩液,用0.22um的滤器对所得水相提取物进行除菌,将过滤后的浓缩液在65℃烘箱中烘干得到梅花草水相提取物,备用;(2) Aqueous phase extraction of plum blossom grass: Weigh 25 grams of dried plum blossom grass, pulverize it with a powder machine, inject 125ml of deionized water, extract it in a water bath at 95°C for 1 hour, filter it, and concentrate it under reduced pressure at 50°C after filtration. liquid, use a 0.22um filter to sterilize the obtained aqueous phase extract, dry the filtered concentrated solution in an oven at 65°C to obtain the aqueous phase extract of Prunus chinensis, and set aside;

(3)将步骤(1)所得的梅花草有机相提取物与步骤(2)所得的梅花草水相提取物等质量混合,即得所述梅花草提取物。(3) Mixing the organic phase extract of Herba Prunus obtained in step (1) with the aqueous phase extract of Herba Prunus obtained in step (2) to obtain the Herba Prunus extract.

实施例3Example 3

梅花草提取物的制备:Preparation of Prunus officinalis extract:

(1)梅花草的有机相提取:取干燥的梅花草全草共0.40kg,使用1000ml的95vol.%乙醇加热至90℃回流提取3次,每次4小时,合并3次提取得到的提取液,挥发乙醇后,得到梅花草乙醇提取物;将上述提取物在喷雾干燥塔中进行干燥得到梅花草有机相提取物,所述喷雾干燥塔进风温度为130℃,出风温度为90℃,雾化频率为250Hz,加料频率为6.5Hz,引风频率为50Hz,能较好保留梅花草固有的芳香物质和热敏性活性成分。(1) Extraction of the organic phase of Prunus chinensis: take 0.40 kg of the whole dried Plum chinensis, use 1000 ml of 95vol.% ethanol to heat to 90 ° C for reflux extraction for 3 times, each time for 4 hours, and combine the extracts obtained from the 3 extractions , after volatilizing ethanol, the ethanol extract of Prunus chinensis is obtained; the above-mentioned extract is dried in a spray drying tower to obtain the organic phase extract of Prunus chinensis, the air inlet temperature of the spray drying tower is 130°C, and the air outlet temperature is 90°C, The atomization frequency is 250Hz, the feeding frequency is 6.5Hz, and the air induction frequency is 50Hz, which can better retain the inherent aromatic substances and heat-sensitive active ingredients of Plum Blossom Grass.

(2)梅花草水相提取:称取25克干燥梅花草,打粉机粉碎后,注入250ml的去离子水在90℃水浴中浸提2小时后过滤,过滤后在55℃减压浓缩得浓缩液,用0.22um的滤器对所得水相提取物进行除菌,将过滤后的浓缩液在70℃烘箱中烘干得到梅花草水相提取物,备用;(2) Water-phase extraction of plum blossom grass: Weigh 25 grams of dried plum blossom grass, pulverize it with a powder machine, inject 250ml of deionized water, extract it in a water bath at 90°C for 2 hours, filter it, and concentrate it under reduced pressure at 55°C after filtration to obtain concentrated liquid, use a 0.22um filter to sterilize the obtained aqueous phase extract, dry the filtered concentrated solution in an oven at 70°C to obtain the aqueous phase extract of Prunus chinensis, and set aside;

(3)将步骤(1)所得的梅花草有机相提取物与步骤(2)所得的梅花草水相提取物等质量混合,即得所述梅花草提取物。(3) Mixing the organic phase extract of Herba Prunus obtained in step (1) with the aqueous phase extract of Herba Prunus obtained in step (2) to obtain the Herba Prunus extract.

效果验证例1Effect verification example 1

琼脂稀释法测定梅花草提取物最小抑菌浓度(minimal inhibitoryconcentration,MIC)Determination of the minimum inhibitory concentration (minimal inhibitory concentration, MIC) of Prunus alba extract by agar dilution method

采用琼脂稀释法测定梅花草提取物的MIC,具体如下:刮取培养48-72小时的Hp接种于液体培养基中,用无菌生理盐水将其稀释至1.5*108CFU/mL。滴加200uL菌液于培养基表面,用涂布棒均匀接种于不同终浓度的梅花草提取物(40g/L、20g/L、10g/L、5g/L、2.5g/L、1.25g/L)的含药平板上,37℃微需氧培养72小时候观察,以未出现Hp生长的最低药物浓度为MIC。MIC测定按美国临床实验室标准化委员会(NCCLS)标判判读结果。The agar dilution method was used to determine the MIC of the extract of Prunus chinensis, specifically as follows: Hp cultured for 48-72 hours was scraped and inoculated in liquid medium, and diluted to 1.5*10 8 CFU/mL with sterile saline. Add 200uL of bacterial solution dropwise on the surface of the culture medium, and inoculate evenly with different final concentrations of Prunus officinalis extracts (40g/L, 20g/L, 10g/L, 5g/L, 2.5g/L, 1.25g/ L) on the drug-containing plate, observe after 72 hours of microaerophilic culture at 37°C, and take the lowest drug concentration at which no Hp growth occurs as the MIC. The results of MIC determination were judged and interpreted according to the National Committee for Clinical Laboratory Standards (NCCLS).

琼脂稀释法测定MIC发现,在20g/L,10g/L的梅花草含药平板中未出Hp,即10g/L为MIC值。该结果提示梅花草提取物具有一定的抗Hp活性。The agar dilution method was used to determine the MIC, and it was found that no Hp appeared in the 20g/L and 10g/L Prunus chinensis drug-containing plates, that is, 10g/L was the MIC value. The results suggested that the extract of Prunus japonica had certain anti-Hp activity.

效果验证例2Effect verification example 2

实时定量PCR检测梅花草提取物对Hp定植粘附相关基因的表达影响Effect of real-time quantitative PCR on the expression of genes related to Hp colonization and adhesion

Hp感染人体首先通过表达Bab A等外膜蛋白粘附在胃黏膜细胞上,再通过表达VacA和Cag A等蛋白诱发炎症和细胞损伤,进而增加胃黏膜的通透性,利于其迁移。Bab A是Hp外膜蛋白基因,可特异性结合宿主细胞受体,赋予Hp持久定植能力;高毒力的Hp菌株具有细胞毒素相关基因(Cag A),参与Cag A转运和宿主的炎症反应。空泡细胞毒素A(Vac A)能够破坏细胞内吞作用,抑制免疫细胞导致免疫耐受和慢性感染,所以进行上述相关基因的引物设计,见表1,并评估梅花草提取物对Hp毒力与定植的影响。Hp infection first expresses Bab A and other outer membrane proteins to adhere to gastric mucosal cells, and then induces inflammation and cell damage by expressing VacA and Cag A proteins, thereby increasing the permeability of gastric mucosa and facilitating its migration. Bab A is the Hp outer membrane protein gene, which can specifically bind to host cell receptors and endow Hp with persistent colonization ability; highly virulent Hp strains have a cytotoxin-related gene (Cag A), which is involved in Cag A transport and host inflammatory response. Vascular cytotoxin A (Vac A) can destroy cell endocytosis, inhibit immune cells and lead to immune tolerance and chronic infection, so the primer design of the above-mentioned related genes is carried out, see Table 1, and the toxicity of Prunella herba extract to Hp and colonization effects.

用蒸馏水溶解梅花草提取物,至终浓度为20mg/ml。将培养的Hp菌液用PBS重悬至1*107CFU/ml,取0.1ml Hp的PBS混悬液加入配好的梅花草提取物溶液中,37℃震荡微氧孵育24小时,离心弃上清,用PBS冲洗3次后,使用RNA prepure Cell/Bacteria Kit(Tiangen公司,中国),分离总的RNA。cDNA的合成按试剂盒(SYBR@primeScriptTM RT-PCR Kit)操作说明即可。引物序列如表1所示。PCR反应体系为:cDNA 2ul,UltraSYBR mixture 25ul,10uM上下游引物各1ul,以去离子水补足至50ul。反应条件,95℃,10min,95℃,10s,60℃,1min,40个循环,采用2-△△CT法计算目的基因相对表达量。并以不添加梅花草提取物溶液的Hp菌液作为对照组(处理方法同上),比较两组中目的基因的相对表达量。Dissolve Prunus chinensis extract in distilled water to a final concentration of 20mg/ml. Resuspend the cultured Hp bacterial solution to 1*10 7 CFU/ml with PBS, add 0.1ml of Hp suspension in PBS to the prepared Prunus chinensis extract solution, incubate at 37°C with shaking and micro-aerobic for 24 hours, centrifuge and discard The supernatant was washed 3 times with PBS, and the total RNA was isolated using RNA prepare Cell/Bacteria Kit (Tiangen Company, China). The cDNA was synthesized according to the operation instructions of the kit (SYBR@primeScript TM RT-PCR Kit). Primer sequences are shown in Table 1. The PCR reaction system is: cDNA 2ul, UltraSYBR mixture 25ul, 10uM upstream and downstream primers 1ul each, made up to 50ul with deionized water. Reaction conditions, 95°C, 10min, 95°C, 10s, 60°C, 1min, 40 cycles, using 2- △△CT method to calculate the relative expression of the target gene. And take the Hp bacteria liquid without adding the Prunus quinquefolium extract solution as the control group (the treatment method is the same as above), and compare the relative expression of the target gene in the two groups.

表1Table 1

Figure BDA0003192082340000071
Figure BDA0003192082340000071

以16S rRNA基因作为内参,采用2-△△CT对对照组及梅花草提取物作用后Hp定植相关基因表达差异进行分析,结果如图1所示。由图1可以看出,梅花草提取物能抑制上述BabA,Cag A和Vac A毒力基因的表达,因此推测,梅花草可通过抑制Hp相关定植与毒力基因的表达,减少Hp对胃黏膜的定植与损伤。Using 16S rRNA gene as an internal reference, 2- △△CT was used to analyze the differences in the expression of Hp colonization-related genes in the control group and after the treatment of Prunus chinensis extract. The results are shown in Figure 1. It can be seen from Figure 1 that the extract of Prunus chinensis can inhibit the expression of the above-mentioned virulence genes of BabA, Cag A and Vac A. Therefore, it is speculated that Prunus chinensis can reduce the effect of Hp on the gastric mucosa by inhibiting the expression of Hp-related colonization and virulence genes. colonization and damage.

效果验证例3Effect verification example 3

动物建模与分组给药观察Animal modeling and group administration observation

幽门螺杆菌的悬液制备:采用微需氧培养法,在微需氧环境下气体达到微需氧条件(85%氮气,10%二氧化碳,5%氧气),将幽门螺杆菌菌株接种于含7%的马血清固体平板上,每100ml固体Hp培养基(Hp固体培养基:Merck空肠弯曲菌培养基20g,加500ml蒸馏水溶解,6.81kg高压灭菌15min,冷却至50℃左右导入50ml羊血及抗生素选择液,混匀后浇注无菌培养板)中添加1ml微生物添加剂,在37℃恒温培养48小时后。经快速尿素酶、氧化酶、涂片革兰氏染色和触酶鉴定为阳性后,用接种环收集细菌,混匀于细菌转送基(细菌转送基:牛心脑浸液6.75g加入500ml蒸馏水溶解,6.81kg高压灭菌15min,冷却至4℃分装备用)中,比浊管控制浓度为1*109CFU/ml备用。Suspension preparation of Helicobacter pylori: adopt microaerophilic culture method, gas reaches microaerophilic condition (85% nitrogen, 10% carbon dioxide, 5% oxygen) under the microaerophilic environment, inoculate Helicobacter pylori bacterial strain in containing 7 % on the horse serum solid plate, every 100ml of solid Hp medium (Hp solid medium: Merck Campylobacter jejuni medium 20g, add 500ml of distilled water to dissolve, 6.81kg autoclave for 15min, cool to about 50 ℃ and import 50ml of sheep blood and Add 1 ml of microbial additives to the antibiotic selection solution (mixed and poured into a sterile culture plate), and incubate at a constant temperature of 37° C. for 48 hours. After being identified as positive by rapid urease, oxidase, smear Gram staining and catalase, the bacteria were collected with an inoculation loop, mixed evenly in the bacterial transfer base (bacterial transfer base: 6.75g of bovine heart and brain infusion was dissolved in 500ml of distilled water , 6.81kg was autoclaved for 15 minutes, cooled to 4°C and dispensed into equipment), and the concentration of the turbidimetric tube was controlled at 1*10 9 CFU/ml for later use.

实验方法:将KM鼠132只,随机分为8组,分别为完全不处理的健康组(以下也简称“正常组”)12只、生理盐水组(Saline组)12只、Hp组18只、三联组18只、四联组18只、梅花草组18只、“三联+梅花草组”18只、“四联+梅花草组”18只,第一天对Hp组、三联组、四联组、梅花草组、“三联+梅花草组”及“四联+梅花草组”的小鼠用幽门螺杆菌悬液灌胃处理,悬液用量为400μL/只,以后隔天灌胃一次,每次200μL/只,4周后,从每组小鼠中各选取3只,评价Hp的感染状态,再确认后,确定各组造模成功,开始对各组小鼠进行给药处理(完全不处理的健康组不予给药、生理盐水组只给予生理盐水、Hp组后期只给予生理盐水、三联组只给予三联药物、四联组只给予四联药物、梅花草组只给予梅花草提取物、“三联+梅花草组”同时给予梅花草提取物和三联药物,“四联+梅花草组”同时给予梅花草提取物和四联药物。其中,梅花草提取物给药量:按标准成人梅花草提取物2000mg bid,根据昆明鼠的体重换算给药量。三联药物给药量:具体参照临床标准成人用量进行换算,70kg成人三联法用量(雷贝拉唑20mg bid,阿莫西林1000mg bid,克拉霉素500mg bid)。四联药物给药量:在成人基础上的四联疗法(雷贝拉唑20mg bid,阿莫西林1000mg bid,克拉霉素500mg bid+胶体果胶铋300mg bid),根据标准成人(70kg)与KM鼠的体重换算。Experimental method: 132 KM mice were randomly divided into 8 groups, including 12 healthy groups (hereinafter also referred to as "normal group") without treatment at all, 12 normal saline groups (Saline group), 18 Hp groups, 18 in the triple group, 18 in the quadruple group, 18 in the plum blossom group, 18 in the "triple + plum blossom group", and 18 in the "quadruple + plum blossom group". group, Plum Blossom Grass group, "triple + Plum Blossom Grass group" and "quadruple + Plum Blossom Grass group" were intragastrically treated with Helicobacter pylori suspension, the amount of suspension was 400 μL/mouse, and then gavaged once every other day. 200 μL/mouse each time, after 4 weeks, 3 mice were selected from each group to evaluate the infection status of Hp. The untreated healthy group was given no drug, the normal saline group was only given normal saline, the Hp group was only given normal saline at the later stage, the triple combination group was only given triple medicine, the quadruple medicine group was only given quadruple medicine, and the Meihuacao group was only given Meihuacao extract. Herb extract and triple drug were administered at the same time in the "triple combination + herb group", and the herb extract and quadruple drug were given at the same time in the "quadruple + herb group". Among them, the dosage of herb extract: according to the standard Adult Plum Blossom Grass Extract 2000mg bid, the dosage is converted according to the body weight of Kunming rats. The dosage of triple drugs: specifically refer to the clinical standard adult dosage for conversion, the dosage of 70kg adult triple method (rabeprazole 20mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid). Quadruple drug dosage: based on adult quadruple therapy (rabeprazole 20mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid + colloidal bismuth pectin 300mg bid) , according to the body weight conversion of standard adults (70kg) and KM mice.

各组小鼠均为间隔一天给药,每天给药1次,每次给药时,将药物置于水中搅拌,得到200μL药液,均在禁食禁水12小时后灌胃给药,给药后半小时给水禁食,连续给药5次,之后牺牲KM鼠,留取血清和解剖胃组织进行相关实验检测,进行快速尿素酶试验(RUT)及HE和Hp的免疫组化染色以及对血清中氧化应激指标进行ELISA检测和对胃黏膜组织的透射电镜分析。The mice in each group were dosed one day apart, once a day, and each time the drug was administered, the drug was stirred in water to obtain 200 μL of the drug solution, which was intragastrically administered after fasting for 12 hours. Fasted with water for half an hour after the drug, administered 5 times in a row, then sacrificed KM mice, collected serum and dissected gastric tissue for relevant experimental detection, carried out rapid urease test (RUT) and immunohistochemical staining of HE and Hp, and analyzed Oxidative stress indicators in serum were detected by ELISA and analyzed by transmission electron microscope on gastric mucosal tissue.

对Hp组和梅花草组小鼠的胃黏膜进行观察,分别如图2(a)和图2(b)所示,由图2可以看出,Hp组小鼠的胃黏膜出血、充血明显,而梅花草提取物组胃黏膜表面光滑,未见糜烂、出血、溃疡。Observe the gastric mucosa of mice in Hp group and Meihuacao group, as shown in Fig. However, the surface of the gastric mucosa in the Prunella extract group was smooth, and no erosion, hemorrhage, or ulcer was seen.

对各组小鼠胃黏膜进行HE染色并观察(100X),如图3所示:正常组胃黏膜结构清晰,Hp感染组可见黏膜脱落,糜烂,黏膜层变薄。三联、四联组可有一定的保护作用,梅花草组可显著增加胃黏膜厚度,保护并促进胃黏膜修复,梅花草提取物联合三联、四联,更能协同保护胃黏膜的结构。HE staining and observation (100X) were performed on the gastric mucosa of mice in each group, as shown in Figure 3: the structure of the gastric mucosa in the normal group was clear, while in the Hp infection group, mucosal exfoliation, erosion, and thinning of the mucosal layer were seen. The triple and quadruple groups can have a certain protective effect. The plum flower group can significantly increase the thickness of the gastric mucosa, protect and promote the repair of the gastric mucosa.

采用快速尿酶法(RUT)对各组小鼠胃黏膜幽门螺杆菌感染情况进行检查,结果如表2所示。The rapid urease method (RUT) was used to detect the Helicobacter pylori infection in the gastric mucosa of mice in each group, and the results are shown in Table 2.

表2Table 2

Figure BDA0003192082340000081
Figure BDA0003192082340000081

Figure BDA0003192082340000091
Figure BDA0003192082340000091

由表2可以看出,梅花草提取物对于幽门螺杆菌感染具有良好的治疗效果,单独的梅花草提取物对于小鼠胃部幽门螺杆菌感染的质量效果优于三联药物的治疗效果,将梅花草提取物与三联或四联联用,能有效提高治愈率。As can be seen from Table 2, the extract of Prunus chinensis has a good therapeutic effect on Helicobacter pylori infection. The combination of grass extract and triple or quadruple can effectively improve the cure rate.

采用透射电镜对各组小鼠胃黏膜细胞的线粒体及胃黏膜微绒毛进行观察,结果分别如图4、图5所示。图4所示:正常组可见线粒体结构完整,内嵴清晰,Hp感染后可见线粒体结构破裂,内嵴紊乱,三联、四联组可在一定程度上修复线粒体的结构,梅花草提取物也对线粒体结构有保护作用,当梅花草提取物联合三联、四联可有效保护线粒体功能,图4结果提示梅花草提取物单一或联合可保护Hp感染后的胃黏膜上皮细胞的线粒体结构。图5所示:正常组可见微绒毛排列整齐,结构较长。而经过Hp感染后,发现微绒毛断裂且消失,经过三联或四联治疗,均有不同程度的恢复。单一的梅花草提取物也可以较好的恢复微绒毛结构,当梅花草提取物联合三联或四联,微绒毛结构整体较好。图5结果提示梅花草提取物单一或联合三联或四联可保护Hp感染后的胃黏膜上皮细胞的微绒毛结构。The mitochondria and gastric mucosal microvilli of the gastric mucosal cells of the mice in each group were observed by transmission electron microscopy, and the results are shown in Figure 4 and Figure 5, respectively. As shown in Figure 4: In the normal group, the mitochondrial structure is complete and the inner cristae are clear. After Hp infection, the mitochondrial structure is broken and the inner crest is disordered. The triple and quadruple groups can repair the structure of the mitochondria to a certain extent. The structure has a protective effect. The combination of triple and quadruple extracts can effectively protect mitochondrial function. The results in Figure 4 suggest that single or combined extracts of plum blossoms can protect the mitochondrial structure of gastric mucosal epithelial cells after Hp infection. As shown in Figure 5: in the normal group, the microvilli were arranged neatly and had a longer structure. However, after Hp infection, the microvilli were found to be broken and disappeared, and after triple or quadruple therapy, they all recovered to varying degrees. A single quince extract can also better restore the microvilli structure. When the quince extract is combined with triple or quadruple, the overall microvilli structure is better. The results in Fig. 5 suggest that the extract of Prunus chinense alone or in combination with triple or quadruple can protect the microvilli structure of gastric mucosal epithelial cells after Hp infection.

采用酶联免疫吸附测定法(ELISA)对各组小鼠血清IL-2、IL-8及TNF-a进行检测,结果如表3所示,单位:pg/mg。The enzyme-linked immunosorbent assay (ELISA) was used to detect serum IL-2, IL-8 and TNF-a of mice in each group, and the results are shown in Table 3, unit: pg/mg.

表3table 3

Figure BDA0003192082340000092
Figure BDA0003192082340000092

Figure BDA0003192082340000101
Figure BDA0003192082340000101

注:*:p<0.05,**:p<0.01。Note: * : p<0.05, ** : p<0.01.

由表3可以看出:通过血清ELISA检测,IL-2,IL-8和TNF-a的表达水平在Hp组显著升高,而经过梅花草提取物处理组,相关炎症因子的水平显著下降,与单纯Hp感染组相比,具有统计学差异(p<0.05),梅花草提取物联合三联、四联治疗组,抗炎、抗氧化效果更明显。It can be seen from Table 3: through serum ELISA detection, the expression levels of IL-2, IL-8 and TNF-a were significantly increased in the Hp group, while the levels of related inflammatory factors were significantly decreased in the group treated with Prunella herba extract, Compared with the simple Hp infection group, there is a statistical difference (p<0.05), and the anti-inflammatory and anti-oxidative effects of the Prunella herba extract combined with triple and quadruple treatment groups are more obvious.

对实施例2和实施例3制备得到的梅花草提取物同样按照上述效果验证例1、效果验证例2及效果验证例3的方法进行上述效果验证,得到的结果与实施例1的梅花草提取物的效果一致。Carry out the above-mentioned effect verification according to the method of above-mentioned effect verification example 1, effect verification example 2 and effect verification example 3 to the Prunus japonica extract prepared by embodiment 2 and embodiment 3, the result obtained is the same as that of the Prunus japonica extract in embodiment 1. The effect is the same.

以上所述,仅为本发明较佳的具体实施方式,本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明披露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围内。The above is only a preferred specific embodiment of the present invention, and the scope of protection of the present invention is not limited thereto. Anyone familiar with the technical field within the technical scope disclosed in the present invention, according to the technical solutions of the present invention and Any equivalent replacement or change of the inventive concepts shall fall within the protection scope of the present invention.

Claims (3)

1.梅花草提取物作为有效组分在制备治疗幽门螺杆菌感染疾病药物中的应用;1. The application of Prunus alba extract as an effective component in the preparation of medicines for treating Helicobacter pylori infection; 所述梅花草提取物的制备方法,包括以下步骤:The preparation method of described plum blossom extract, comprises the following steps: 梅花草有机相提取物的制备:采用95vol.%的乙醇对梅花草进行加热回流提取得到提取液,之后除去提取液中的乙醇,喷雾干燥后得到梅花草有机相提取物;其中,梅花草与乙醇的料液比为1g∶(1~5mL),加热温度为90-95℃,每次提取4h,共提取3次,合并3次所得的提取液;The preparation of the organic phase extract of Prunus officinalis: use 95vol.% ethanol to heat and reflux the Prunus officinalis to extract the extract, then remove the ethanol in the extract, and spray dry to obtain the organic phase extract of Prunus officinalis; wherein, Prunus officinalis and The solid-liquid ratio of ethanol is 1g: (1-5mL), the heating temperature is 90-95°C, each extraction is 4h, a total of 3 extractions are made, and the extracts obtained from the 3 extractions are combined; 梅花草水相提取物的制备:采用水对梅花草进行加热浸提,过滤得浸提液,之后浓缩,对得到的浓缩液干燥,得到梅花草水相提取物;其中,梅花草与水的料液比为1g∶(5~10mL),加热温度为90-95℃,浸提时间为1-2h,所述浓缩具体为在50-60℃下减压浓缩,所述干燥温度为65-75℃;The preparation of the water-phase extract of Prunus chinensis: heating and leaching Plum blossom with water, filtering to obtain the extract, then concentrating, and drying the obtained concentrated solution to obtain the aqueous phase extract of Prunus quince; The ratio of solid to liquid is 1g: (5-10mL), the heating temperature is 90-95°C, the extraction time is 1-2h, the concentration is specifically concentrated under reduced pressure at 50-60°C, and the drying temperature is 65- 75°C; 将所述梅花草有机相提取物及所述梅花草水相提取物等质量混合后得到所述梅花草提取物。The Herba Prunus organic phase extract and the Herba Prunus aqueous phase extract are mixed in equal mass to obtain the Herba Prunus officinalis extract. 2.根据权利要求1所述的应用,其特征在于,所述幽门螺杆菌感染疾病为胃炎、胃溃疡、十二指肠溃疡或胃癌。2. The application according to claim 1, characterized in that the Helicobacter pylori infection disease is gastritis, gastric ulcer, duodenal ulcer or gastric cancer. 3.根据权利要求1所述的应用,其特征在于,所述梅花草提取物作为有效组分加入药学上可接受的辅料制成片剂、胶囊剂、颗粒剂、口服液、悬浮剂或注射液,各种剂型中梅花草提取物的质量占药物总质量的30-60%。3. application according to claim 1, is characterized in that, described plum blossom extract is added pharmaceutically acceptable adjuvant as effective component to make tablet, capsule, granule, oral liquid, suspension or injection Liquid, the quality of the plum blossom extract in various dosage forms accounts for 30-60% of the total medicine mass.
CN202110880525.9A 2021-08-02 2021-08-02 Application of Plum Blossom Extract in the Preparation of Medicines for Helicobacter pylori Infection Active CN113413402B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110880525.9A CN113413402B (en) 2021-08-02 2021-08-02 Application of Plum Blossom Extract in the Preparation of Medicines for Helicobacter pylori Infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110880525.9A CN113413402B (en) 2021-08-02 2021-08-02 Application of Plum Blossom Extract in the Preparation of Medicines for Helicobacter pylori Infection

Publications (2)

Publication Number Publication Date
CN113413402A CN113413402A (en) 2021-09-21
CN113413402B true CN113413402B (en) 2022-11-04

Family

ID=77718673

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110880525.9A Active CN113413402B (en) 2021-08-02 2021-08-02 Application of Plum Blossom Extract in the Preparation of Medicines for Helicobacter pylori Infection

Country Status (1)

Country Link
CN (1) CN113413402B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657091B (en) * 2022-03-03 2023-08-11 中国疾病预防控制中心传染病预防控制所 A kind of campylobacter enrichment culture solution and its preparation method and application
CN120501702B (en) * 2025-07-18 2026-02-10 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) A Ulidige antibacterial gel and its preparation method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102824417A (en) * 2011-09-26 2012-12-19 王子厚 New method for treating helicobacter pylori related diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109966329A (en) * 2019-05-18 2019-07-05 临沂市德力康医疗康复器械有限公司 A kind of application of star extract in treatment acpuei pharyngitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102824417A (en) * 2011-09-26 2012-12-19 王子厚 New method for treating helicobacter pylori related diseases

Also Published As

Publication number Publication date
CN113413402A (en) 2021-09-21

Similar Documents

Publication Publication Date Title
CN112691114B (en) Application of momordica polysaccharide in preparation of medicine for treating ulcerative colitis and pharmaceutical preparation of momordica polysaccharide
KR102084973B1 (en) Composition for preventing or treating colitis comprising enterococcus faecalis
TWI598104B (en) Use of Antrodia cinnamomea extract to improve side effects of chemotherapy
CN117064920B (en) Application of Akkermansia muciniphila in preparing products for preventing, treating and/or assisting in treating tumors
CN110859845A (en) Application of tanshinone compound
CN113413402A (en) Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection diseases
Chen et al. Qiguiyin Decoction Improves Multidrug‐Resistant Pseudomonas aeruginosa Infection in Rats by Regulating Inflammatory Cytokines and the TLR4/MyD88/NF‐κB Signaling Pathway
CN107184815B (en) Traditional Chinese medicine composition for treating tuberculous ulcer and sinus, preparation method and application thereof
CN118662509B (en) Application of Bamipine hydrochloride in the preparation of medicine for treating aortic valve calcification
Wu et al. Tuoli Xiaodu powder ameliorated 5-fluorouracil-induced intestinal injury by reducing intes-tinal inflammation, oxidative stress, and intestinal flora imbalance
CN103191175B (en) Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof
CN114306453B (en) Application of pharmaceutical composition in preparation of medicines for treating inflammatory bowel disease
CN116966206A (en) Use of Lactobacillus fermentum for the preparation of products for the prevention and/or treatment of purgative colon
CN116509888A (en) Application of garlic polysaccharide in the preparation of drugs for intestinal flora disturbance caused by acute lung injury
CN102076346B (en) Pharmaceutical compositions for human and preparation of bismuth or zinc agent
CN108186740A (en) Meadowrueleaf corydalis root prepares treatment intestinal disorder drug or health products and application with its extract
CN116172997A (en) Application of Phenyllactic Acid in Inhibiting Helicobacter Pylori Infection
CN101336916A (en) Uses of tea polyphenols
CN103239538B (en) A kind of gastropathy drug composition of anti-helicobacter pylori
CN109419787A (en) A kind of purposes of Diterpene class compound
CN117379467B (en) Pharmaceutical composition for treating digestive tract diseases and preparation method thereof
CN120227365B (en) Use of 2,6-dimethoxy-1,4-benzoquinone in the preparation of drugs for treating colitis and/or peritonitis
CN110974822B (en) Pharmaceutical use of ammonium pyrrolidine dithiocarbamate
CN108853081A (en) Medical application of the amentoflavone in treatment chicken necrotizing enterocolitis
CN114159533B (en) Traditional Chinese medicine composition for treating multiple drug-resistant bacterial infection and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210921

Contract record no.: X2026980008772

Denomination of invention: The application of Pulsatilla extract in the preparation of drugs for treating Helicobacter pylori infection diseases

Granted publication date: 20221104

License type: Common License

Record date: 20260528